ArticleBMC microbiology2026
Evaluating Proteus mirabilis phage vB_PmiA_PM1 efficacy against catheter-associated urinary tract infections in artificial urine and laboratory media.
Article in BMC microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Proteus mirabilis is a leading cause of catheter-associated urinary tract infections (CAUTI) because of its capability to develop extensive crystalline biofilms that obstruct catheters. Phages can effectively eradicate P. mirabilis biofilms in vitro; however, the clinical trial outcomes have been controversial. The current study aimed to investigate phage efficacy against P. mirabilis CAUTI in artificial urine medium (AUM) and laboratory media. A novel lytic P. mirabilis phage, vB_PmiA_PM1, was isolated and characterized. The phage had a narrow host range, capable of infecting only its main host strain, indicating high specificity. The phage also showed short latency, a large burst size, and physiochemical stability. The phage genome is linear double-stranded DNA (42,188 bp) with 59 open reading frames and closely resembles Salmonella phage vB_SpuP_Spp16. A putative depolymerase with a peptidoglycan hydrolase domain was identified within the phage tail protein, highlighting its role in the degradation of bacterial cells and the biofilm matrix. The bacteriolytic and biofilm-eradicating activities of this phage differed considerably between AUM and laboratory-rich media. Additionally, the growth dynamics of P. mirabilis in AUM exhibited less abundant growth as compared to that in trypticase soya broth. In addition, the formation of diverse struvite crystal morphotypes occurred as the pH increased. However, in the presence of vB_PmiA_PM1 phage, one morphotype of coffin-lid crystal was observed, which increased over time. Furthermore, phage activity on silicone Foley catheter sections demonstrated altered biofilm architecture and swarming migration in both media. These findings highlight the discrepancies between laboratory testing of phage and its clinical applications, which might fill the gaps in the future success of phage therapy against biofilm-associated CAUTI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.